PMID- 36894194
OWN - NLM
STAT- MEDLINE
DCOM- 20230313
LR  - 20230410
IS  - 2056-5933 (Electronic)
IS  - 2056-5933 (Linking)
VI  - 9
IP  - 1
DP  - 2023 Mar
TI  - Stable incidence but increase in prevalence of ANCA-associated vasculitis in 
      southern Sweden: a 23-year study.
LID - 10.1136/rmdopen-2022-002949 [doi]
LID - e002949
AB  - OBJECTIVE: To update the epidemiology of anti-neutrophil cytoplasmic 
      antibody-associated vasculitis (AAV) in a defined geographical area of southern 
      Sweden. METHODS: The study area comprised 14 municipalities with a combined adult 
      population (>/=18 years) of 623 872 in 2019. All cases diagnosed with AAV in 
      1997-2019 in the study area were included in the estimate of incidence. Diagnosis 
      of AAV was verified by case record review, and cases were classified using the 
      European Medicines Agency algorithm. Point prevalence was estimated on 01 January 
      2020. RESULTS: Three hundred and seventy-four patients (median age 67.5 years, 
      47% female) were diagnosed with new-onset AAV during the study period. One 
      hundred and ninety-two were classified as granulomatosis with polyangiitis (GPA), 
      159 as microscopic polyangiitis (MPA) and 23 as EGPA. The average annual 
      incidence/million adults was 30.1 (95% CI 27.0 to 33.1) for AAV: 15.4 (95% CI 
      13.3 to 17.6) for GPA, 12.8 (95% CI 10.8 to 14.8) for MPA and 1.8 (95% CI 1.1 to 
      2.6) for eosinophilic GPA (EGPA). Incidence was stable during the study period, 
      30.3/million 1997-2003, 30.4/million 2004-2011 and 29.5/million 2012-2019. The 
      incidence increased with age and was highest in age group 70-84 years (96/million 
      adults). On 1 January 2020, the prevalence was 428/million adults and was higher 
      in males than in females (480 vs 378/million). CONCLUSIONS: The incidence of AAV 
      in southern Sweden was found stable over the course of 23 years; while the 
      prevalence has increased, which might indicate better management and treatment of 
      AAV resulting in improved survival.
CI  - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published 
      by BMJ.
FAU - Rathmann, Jens
AU  - Rathmann J
AUID- ORCID: 0000-0001-5085-7684
AD  - Clinical Sciences, Rheumatology, Lund University, Lund, Sweden.
FAU - Segelmark, Marten
AU  - Segelmark M
AD  - Department of Nephrology, Lund University, Lund, Sweden.
FAU - Englund, Martin
AU  - Englund M
AD  - Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, 
      Lund University, Lund, Sweden.
FAU - Mohammad, Aladdin J
AU  - Mohammad AJ
AUID- ORCID: 0000-0002-7169-6936
AD  - Clinical Sciences, Rheumatology, Lund University, Lund, Sweden 
      aladdin.mohammad@med.lu.se.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - RMD Open
JT  - RMD open
JID - 101662038
SB  - IM
MH  - Adult
MH  - Male
MH  - Humans
MH  - Female
MH  - Aged
MH  - Aged, 80 and over
MH  - Prevalence
MH  - Sweden/epidemiology
MH  - Incidence
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/epidemiology
MH  - *Granulomatosis with Polyangiitis/epidemiology
MH  - *Microscopic Polyangiitis/epidemiology/therapy
PMC - PMC10008447
OTO - NOTNLM
OT  - Epidemiology
OT  - Granulomatosis with polyangiitis
OT  - Systemic vasculitis
COIS- Competing interests: None declared.
EDAT- 2023/03/10 06:00
MHDA- 2023/03/14 06:00
PMCR- 2023/03/09
CRDT- 2023/03/09 20:52
PHST- 2022/12/19 00:00 [received]
PHST- 2023/02/05 00:00 [accepted]
PHST- 2023/03/09 20:52 [entrez]
PHST- 2023/03/10 06:00 [pubmed]
PHST- 2023/03/14 06:00 [medline]
PHST- 2023/03/09 00:00 [pmc-release]
AID - rmdopen-2022-002949 [pii]
AID - 10.1136/rmdopen-2022-002949 [doi]
PST - ppublish
SO  - RMD Open. 2023 Mar;9(1):e002949. doi: 10.1136/rmdopen-2022-002949.